NUP98-KDM5A巨核细胞白血病小鼠人源模型揭示新生物标志物与治疗脆弱性
该研究利用慢病毒在人类脐带血造血干祖细胞中过表达NUP98-KDM5A,构建生理相关的急性巨核细胞白血病(AMKL)模型;模型细胞在免疫缺陷小鼠中可诱发包括AMKL在内的多种白血病,并鉴定出SELP、MPIG6B、NEO1为新生物标志物,JAK-STAT通路上调,且对芦可替尼(ruxolitinib)敏感。
要点
- NUP98-KDM5A过表达人脐血干祖细胞可致成熟阻滞并长期维持增殖。
- 移植模型可重现人AMKL表型与分子特征。
- SELP、MPIG6B、NEO1为新型AMKL生物标志物;JAK-STAT上调,芦可替尼有体外活性。
核心结论
- 合成人AMKL模型可定义高致死性罕见基因型儿童白血病功能依赖,并揭示治疗脆弱性。
研究设计与样本
- 利用慢病毒在人类脐带血造血干祖细胞中过表达NUP98-KDM5A,构建生理相关疾病模型。
- 将NUP98-KDM5A转化细胞 adoptive transfer 至免疫缺陷小鼠。
主要发现
- NUP98-KDM5A融合癌基因是成熟阻滞强诱导因素,在优化培养条件下维持工程细胞长期增殖与祖细胞能力。
- 移植后小鼠发生包括AMKL在内的多种白血病亚型,表型和分子上模拟人类疾病。
- 合成与患者NUP98-KDM5A AMKL样本整合分子特征显示SELP、MPIG6B、NEO1为独特新生物标志物。
- 转录组和蛋白质组分析提示模型AMKL中JAK-STAT信号通路上调。
- 合成模型和NUP98重排AMKL患者来源异种移植(PDX)体外对芦可替尼(JAK2抑制剂)显示治疗脆弱性。
关键数值与推荐
- AMKL约占儿童急性髓系白血病病例的10%,通常影响年幼儿童(<3岁)。
- 治疗结局极差(治愈率<40%),主要因原发化疗难治和/或早期复发。
- 60%至70%病例检测到复发且互斥的嵌合融合癌基因,包括NUP98基因重排,最常见为NUP98-KDM5A。
临床怎么用
- SELP、MPIG6B、NEO1可作为NUP98-KDM5A AMKL的新型生物标志物。
- 芦可替尼(JAK2抑制剂)在体外对NUP98重排AMKL模型和PDX显示治疗脆弱性,提示JAK-STAT通路为潜在靶点。
局限性
- 患者样本罕见,限制生物标志物和药物发现。
- 缺乏忠实重现NUP98-KDM5A驱动AMKL的人源模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute megakaryoblastic leukemia (AMKL) represents ∼10% of pediatric acute myeloid leukemia cases and typically affects young children (<3 years of age). It remains plagued with extremely poor treatment outcomes (<40% cure rates), mostly due to primary chemotherapy refractory disease and/or early relapse. Recurrent and mutually exclusive chimeric fusion oncogenes have been detected in 60% to 70% of cases and include nucleoporin 98 (NUP98) gene rearrangements, most commonly NUP98-KDM5A. Human models of NUP98-KDM5A-driven AMKL capable of faithfully recapitulating the disease have been lacking, and patient samples are rare, further limiting biomarkers and drug discovery. To overcome these impediments, we overexpressed NUP98-KDM5A in human cord blood hematopoietic stem and progenitor cells using a lentiviral-based approach to create physiopathologically relevant disease models. The NUP98-KDM5A fusion oncogene was a potent inducer of maturation arrest, sustaining long-term proliferative and progenitor capacities of engineered cells in optimized culture conditions. Adoptive transfer of NUP98-KDM5A-transformed cells into immunodeficient mice led to multiple subtypes of leukemia, including AMKL, that phenocopy human disease phenotypically and molecularly. The integrative molecular characterization of synthetic and patient NUP98-KDM5A AMKL samples revealed SELP, MPIG6B, and NEO1 as distinctive and novel disease biomarkers. Transcriptomic and proteomic analyses pointed to upregulation of the JAK-STAT signaling pathway in the model AMKL. Both synthetic models and patient-derived xenografts of NUP98-rearranged AMKL showed in vitro therapeutic vulnerability to ruxolitinib, a clinically approved JAK2 inhibitor. Overall, synthetic human AMKL models contribute to defining functional dependencies of rare genotypes of high-fatality pediatric leukemia, which lack effective and rationally designed treatments.
引用
- Cardin S, Bilodeau M, Roussy M, et al. Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. Blood Adv. 2019. PMID: 31698461. doi:10.1182/bloodadvances.2019030981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。